Rachel M Layman, MD

Peer-Reviewed Articles

1. Iwase R, Sridhar N, Kai M, Dong W, Shen Y, Krishnamurthy S, Lucci A, Le-Petross HTC, Nasrazadani A, Saleem S, Layman RM, Valero V, Tripathy D, Woodward WA, Cheng YC, Nakhlis F, Bellon JR, Lynce F, Ueno NT. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Can Res and Treatment 214(1):69-77, 2025. e-Pub 2025. PMID: 40753318.
2. Wesolowski R, Rugo HS, Specht JM, Han H, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer. Clin Cancer Res 31(19):4040-4048, 2025. e-Pub 2025. PMID: 40711480.
3. Mughees M, Tacam M, Tan A, Pitner M, Iles L, White M, Hu X, Villodre ES, Debeb B, Kogawa T, Lim B, Layman R, Woodward W, Ueno N, Tripathy D, Krishnamurthy S, Qi Y, Pusztai L, Wang J, Gandhi V, Bartholomeusz G, Bartholomeusz C. Inhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers. Mol Cancer Ther 24(9):1453-1465, 2025. e-Pub 2025. PMID: 40358476.
4. Rugo, H, Layman, RM, Lynce, F, Liu, X, Li, B, McRoy, L, Cohen, AB, Estevez, M, Curigliano, G, Brufsky, AM. Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open 10(9), 2025. e-Pub 2025. PMID: 40896879.
5. Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO Open 10(7):105297, 2025. e-Pub 2025. PMID: 40532364.
6. Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy. Lancet Oncol 26(7):e332-e333, 2025. e-Pub 2025. PMID: 40609573.
7. Hu X, Xiong Y, Villodre ES, Zhang H, Song J, Fowlkes N, Krishnamurthy S, Rylander M, Bartholomeusz C, Tripathy D, The MDACC Inflammatory Breast Cancer Team, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin Drives Brain Metastasis in Inflammatory Breast Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40667060.
8. Layman RM, Liu X, Li B, McRoy L, Brufsky A. Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast 81(104448), 2025. e-Pub 2025. PMID: 40138984.
9. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary. Future Oncol 21(11):1287-95, 2025. e-Pub 2025. PMID: 40159782.
10. Kouzy R, Kai M, Le-Petross HT, Saleem S, Cancer Team MIB, Woodward WA. Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system. JNCI Cancer Spectr 9(3):pkaf058, 2025. e-Pub 2025. PMID: 40493814.
11. Raghavendra AS, Jr BR, Damodaran S, Barcenas CH, Mouabbi JA, Layman R, Tripathy D. Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma. JAMA Netw Open 8(4):e251888, 2025. e-Pub 2025. PMID: 40293750.
12. Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Muñoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol 43(9):1101-12, 2025. e-Pub 2025. PMID: 39693591.
13. Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B. Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 210(1):179-89, 2025. e-Pub 2025. PMID: 39644403.
14. Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting. ESMO Open 10(1):104103, 2025. e-Pub 2025. PMID: 39754979.
15. Lim B, Marx A, Kai M, Alexander A, Bassett R Jr, Ma W, Willey J, Sun H, Nasrazadani A, Mohammad MM, Zhang J, Lucci A, Sun SX, Stauder MC, Whitman GJ, Le-Petross H, Valero V, Woodward WA, Layman RM. A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease). Ther Adv Med Oncol 17:17588359251379392, 2025. e-Pub 2025. PMID: 41116969.
16. Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Rugo HS. Palbociclib Plus Aromatase Inhibitors in Patients With Metastatic Breast Cancer and Cardiovascular Diseases: Real-World Effectiveness. Oncologist 29(12):1032-43, 2024. e-Pub 2024. PMID: 39418346.
17. Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolò E, Ribeiro JM, Guidi L, Reduzzi C, Spotti M, Adamoli L, Cortès J, Pistilli B, Tolaney SM, Ueno N, Layman RM, Cristofanilli M, Carey LA, Munzone E, Criscitiello C, Lynce F, Woodward WA, Curigliano G. Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study. Eur J Cancer 213, 2024. e-Pub 2024. PMID: 39486164.
18. Glencer AC, Wanis KN, Brown S, Lucci A, Sun SX, Adesoye T, DeSnyder SM, Layman R, Woodward WA, Hunt KK, Teshome M. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Ann Surg Oncol 31(11):7326-34, 2024. e-Pub 2024. PMID: 39034365.
19. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med 30(8):2242-50, 2024. e-Pub 2024. PMID: 38824244.
20. Glencer AC, Wanis KN, Brown S, Lucci A, Sun SX, Adesoye T, DeSnyder SM, Layman R, Woodward WA, Hunt KK, Teshome M. ASO Visual Abstract: Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership-Consensus and Opportunities, 2024. e-Pub 2024. PMID: 39126436.
21. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med 5(6):101595, 2024. e-Pub 2024. PMID: 38838676.
22. Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res 30(11):2424-32, 2024. e-Pub 2024. PMID: 38629963.
23. Nakhlis F, Niman SM, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Carisa Le-Petross HT, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan M, Lynce F, Layman RM. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Breast Cancer Res Treat 204(2):289-97, 2024. e-Pub 2024. PMID: 38155272.
24. Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Gedatolisib in combination with palbociclib and endocrine therapy in women with HR+, HER2- advanced breast cancer: results from the dose expansion arms of an open-label, phase 1b study. Lancet Oncol 25(4):474-87, 2024. e-Pub 2024. PMID: 38547892.
25. Mouabbi JA, Qaio W, Shen Y, Raghavendra AS, Tripathy D, Layman RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist 29(3):213-8, 2024. e-Pub 2024. PMID: 38070191.
26. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. Int J Cancer 154(4):701-711, 2024. e-Pub 2024. PMID: 37831416.
27. Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA. A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced or Metastatic Breast Cancer. Clin Cancer Res 30(2):334-43, 2024. e-Pub 2024. PMID: 37992310.
28. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Tomlin-Harris T, Brufsky A. Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study. Future Oncol 20(19):1299-1307, 2024. e-Pub 2024. PMID: 38517416.
29. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary. Future Oncol 20(19):1309-17, 2024. e-Pub 2024. PMID: 38536033.
30. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice. Cancers 15(21), 2023. e-Pub 2023. PMID: 37958441.
31. Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer. Oncologist 28(10):866-74, 2023. e-Pub 2023. PMID: 37487056.
32. Mouabbi JA, Raghavendra AS, Bassett Jr RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman, RM. Absence of Lobular Carcinoma In Situ is a Poor Prognostic Marker in Invasive Lobular Carcinoma. European Journal of Cancer 191:113250. doi: 10.1016/j.ejca.2023.113250, 2023. e-Pub 2023. PMID: 37573674.
33. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-69, 2023. e-Pub 2023. PMID: 37061619.
34. Rugo HS, Liu X, Li B, McRoy L, Layman RM, Adam Brufsky A. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. Breast 69:375-81, 2023. e-Pub 2023. PMID: 37080011.
35. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
36. Mouabbi JA, Singareeka Raghavendra A, Jr BR, Hassan A, Tripathy D, Layman RM. Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy. JAMA Netw Open 6(5):e2313017, 2023. e-Pub 2023. PMID: 37166793.
37. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol 13, 2023. e-Pub 2023. PMID: 37841423.
38. Mouabbi, JA, Singareeka Raghavendra, A, Bassett Jr, R, Hassan, A, Tripathy, D, Layman, RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. npj Breast Cancer 8(1), 2022. e-Pub 2022. PMID: 36539444.
39. Corrigan KL, Kouzy R, Jaoude JA, Patel RR, Layman RM, Giordano SH, Woodward WA, Smith BD, Shaitelman SF, Ludmir EB. Inclusion of premenopausal women in breast cancer clinical trials. Breast 66:204-207, 2022. e-Pub 2022. PMID: 36327626.
40. Rugo, H, Brufsky, AM, Liu, X, Li, B, McRoy, L, Chen, C, Layman, RM, Cristofanilli, M, Torres, M, Curigliano, G, Finn, RS, DeMichele, A. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer. npj Breast Cancer 8(1), 2022. e-Pub 2022. PMID: 36220852.
41. Cobb AN, Diao K, Lucci A, Teshome M, Woodward W, Ueno NT, Stauder M, Layman RM, Sun SX. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol 29(10):6381-92, 2022. e-Pub 2022. PMID: 35834145.
42. Patt, DA, Liu, X, Li, B, McRoy, L, Layman, RM, Brufsky, AM. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer. Clinical breast cancer 22(6):601-10, 2022. e-Pub 2022. PMID: 35643624.
43. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases. Front Oncol 12, 2022. e-Pub 2022. PMID: 35860587.
44. Ha MH, Raghavedra AS, Kettner NM, Damodaran S, Layman RM, Hunt KK, Shen U, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients as compared to endocrine therapy alone in the second line setting - A large institutional study. Int J Cancer 150(12):2025-37, 2022. e-Pub 2022. PMID: 35133007.
45. Layman RM, Lin H, Gutierrez Barrera AM, Karaturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med 11(6):1474-1483, 2022. e-Pub 2022. PMID: 35128817.
46. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol 16(5):601-11, 2021. e-Pub 2021. PMID: 34338965.
47. Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer. Clin Can Res 27(21):5760-5770, 2021. e-Pub 2021. PMID: 34433648.
48. Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy. Ann Oncol 32(5):642-51, 2021. e-Pub 2021. PMID: 33617937.
49. DeMichele, A, Cristofanilli, M, Brufsky, A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res 23(1):37, 2021. e-Pub 2021. PMID: 33761995.
50. Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelrahim M, Diab A, Yee C, Abdelwahab N. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1), 2021. e-Pub 2021. PMID: 33643693.
51. Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs 38(5):1400-1410, 2020. e-Pub 2020. PMID: 31953695.
52. Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J 26(8):1572-1582, 2020. e-Pub 2020. PMID: 32497289.
53. Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. Phase I study of veliparib on an intermittent and continuous schedule in combination with carboplatin in metastatic breast cancer: a safety and [18F]-fluorothymidine positron emission tomography biomarker study. Oncologist 25(8):e1158-e1169, 2020. e-Pub 2020. PMID: 32452601.
54. Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Sinn BV, Layman R, Bedrosian I, Valero V, Symmans WF. Technical validity of a customized assay of sensitivity to endocrine therapy using sections from fixed breast cancer tissue. Clin Chem 66(7):934-45, 2020. e-Pub 2020. PMID: 32613237.
55. Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer 20(1):430, 2020. e-Pub 2020. PMID: 32423453.
56. Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, WErd C. Exploratory analysis of immune checkpoint receptor expression by circulating t cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer 20(1):445, 2020. e-Pub 2020. PMID: 32429929.
57. Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W. SET ER/PR: A robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer 5(16), 2019. e-Pub 2019. PMID: 31231679.
58. Makary MS, Lionberg A, Khayat M, Lustberg MB, AlTaani J, Pan XJ, Layman RR, Raman SV, Layman RM, Dowell JD. Advanced stage breast cancer is associated with catheter-tip thrombus formation following implantable central venous port placement. Phlebology 34(2):268355518774442, 2018. e-Pub 2018. PMID: 29771187.
59. Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro CL, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Res Treat 167(3):709-718, 2018. e-Pub 2018. PMID: 29101597.
60. Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother 66(11):1437-1447, 2017. e-Pub 2017. PMID: 28688082.
61. Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Randomized phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer. Oncologist 22(3):245-254, 2017. e-Pub 2017. PMID: 28220020.
62. Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Clinical and translational results of a phase II, randomized trial of an anti-IGF-1R (Cixutumumab) in women with breast cancer that progressed on endocrine therapy. Clin Cancer Res 22(2):301-9, 2016. e-Pub 2016. PMID: 26324738.
63. Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R, Shapiro C, Malarkey WB, Emery CF, Layman R, Mrozek E, Glaser R, Kiecolt-Glaser JK. Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology 24(8):958-66, 2015. e-Pub 2015. PMID: 25336068.
64. Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23(7):2019-24, 2015. e-Pub 2015. PMID: 25519756.
65. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast cancer risk reduction (Version 2.2015). J Natl Compr Canc Netw 13(7):880-915, 2015. e-Pub 2015. PMID: 26150582.
66. Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncologist 20(4):337-43, 2015. e-Pub 2015. PMID: 25732265.
67. Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs 32(6):1285-94, 2014. e-Pub 2014. PMID: 24894652.
68. Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer 14(4):228-34, 2014. e-Pub 2014. PMID: 24703985.
69. Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, Emery CF, Layman RM, Mrozek EE, Glaser R. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol 32(10):1040-9, 2014. e-Pub 2014. PMID: 24470004.
70. Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res 16(2):R23, 2014. e-Pub 2014. PMID: 24602188.
71. Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 21(10):2679-86, 2013. e-Pub 2013. PMID: 23686402.
72. Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RM. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Support Care Cancer 21(10):2845-51, 2013. e-Pub 2013. PMID: 23748485.
73. Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol 71(5):1183-90, 2013. e-Pub 2013. PMID: 23430121.
74. Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 19(6):1512-24, 2013. e-Pub 2013. PMID: 23340294.
75. Reinbolt RE, Alam S, Layman R, Shapiro C, Lustberg M. Pneumocystis jiroveci pneumonia in an atypical host. Clin Breast Cancer 12(2):138-41, 2012. e-Pub 2012. PMID: 22133356.
76. Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CL. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. Clin Breast Cancer 12(2):151-6, 2012. e-Pub 2012. PMID: 22444722.
77. Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 11(4):221-7, 2011. e-Pub 2011. PMID: 21729671.
78. Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, Hayes DF, Schott AF. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 13(14):4092-7, 2007. e-Pub 2007. PMID: 17634534.
79. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 13(2 Pt 1):443-50, 2007. e-Pub 2007. PMID: 17255264.
80. Akshara S Raghavendra, Senthil Damodaran, Carlos H Barcenas, Suzanne A Fuqua, Rachel M Layman, Debu Tripathy. Personalizing therapies over the course of hormone receptor–positive/HER2-negative metastatic breast cancer" (CA-25-0081.R1). CA: A Cancer Journal for Clinicians.
81. Hamilton E, Layman R, Cosgrove D, Danso M, He W, Kim S, Patel M. ER degradation for ER+/HER2‒ advanced or metastatic breast cancer: a phase 1 trial. Nature Communications.
82. Nasrazadani A, Tidwell RS, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Debeb BG, Lucci A, Clinic MI, Team R, Woodward WA, Layman RM. Retrospective Review of Metastatic Hormone Receptor-Positive Inflammatory Breast Cancer Patients Reveals Poor Responses to Cyclin Dependent Kinase 4/6 Inhibition. Breast Cancer Research.

Invited Articles

1. Layman RM, and Arun B. PARP inhibitors in triple negative breast cancer including those with BRCA mutations. The Cancer Journal 27(1):67-75, 2021. e-Pub 2021. PMID: 33475295.
2. Layman RM. CDK4/6 inhibitors for advanced hormone receptor-positive breast cancer, 2019 and beyond. J Natl Compr Canc Netw 17(2):190-2, 2019. e-Pub 2019. PMID: 30787131.
3. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in cancer therapy: Current evidence and future directions. Target Oncol 13(1):21-38, 2018. e-Pub 2018. PMID: 29218622.
4. Layman R, Olson K, Van Poznak C. Bisphosphonates for Breast Cancer: Questions Answered, Questions Remaining. Hematol Oncol Clin North Am 21(2):341-67, 2017. e-Pub 2017. PMID: 17512453.
5. Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: Questions answered, questions remaining. Hematol Oncol Clin North Am 21(2):341-67, 2007. e-Pub 2007. PMID: 17512453.

Review Articles

1. Mouabbi, JA, Hassan, A, Lim, B, Hortobagyi, GN, Tripathy, D, Layman, RM. Invasive lobular carcinoma. Breast Cancer Research and Treatment 193(2):253-264, 2022. e-Pub 2022. PMID: 35347549.

Other Articles

1. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med 30(8):2371, 2024. PMID: 38914862.
2. Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary. Future Oncol 19(7):489-98, 2023. PMID: 36892508.
3. Brufsky A, Liu X, Li B, McRoy L, Layman RM Correction to: Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol 16(6):865, 2021. PMID: 34652714.
4. Braschi EL, Yang Y, Stauder MC, Woodward A, Layman RM, Lim B, Arnold T, Lucci S, Sun SX, Saleem S, Ludmir EB, Corrigan KL Exclusion of Inflammatory Breast Cancer Patients from Breast Cancer Clinical Trials.

Abstracts

1. Haney J, Pedroza DA, Marx A, Alexander A, Tidwell R, Nasrazadani A, Layman R, Valero V, Sun H, Lucci A, Sun S, Le-Petross C, Whitman G, Sheth R, Krishnamurthy S, Goodman C, Stauder M, Woodward WA, Rosen J, Lim B. A phase Ib study of novel combination (New) of low dose oral cyclophoSphamide (S) To potentiate axatilimab (A) + retifanlimab (R) in treating metastatic Triple negative breast cancer (NEW START). 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
2. Mukohara T, LoRusso PM, Sommerhalder D, Yonemori K, Hamilton E, Kim S, Im S, Lindeman GJ, Rugo HS, Iwata H, Layman RM, Kim GM, Yamashita T, Kim JH, Yan F, Shimizu T, Chae YS, Clay T, Joshi R, Mita M, Hui M, Dong B, Holbrook B, Kent S, Skoura A, Liu L, Li M, Park YH. PF-07248144, a first-in-class KAT6 inhibitor, in patients with HR+ HER2− metastatic breast cancer: Updated results from phase 1 dose expansion study. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
3. Nasrazadani A, Tidwell R, Kai M, Layman RM, Lim B, Valero V, Saleem S, Lucci A, Stauder M, Sun SX, Cancer Team MIB, Woodward W. 1000 Patient Prospective Inflammatory Breast Cancer (IBC) Registry Demonstrates Advances in Outcomes for IBC. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
4. Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Comparative overall survival of CDK4/6is plus an aromatase inhibitor (AI) in HR+/HER2- MBC in the US real-world setting. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
5. Hilton J, Jerzak KJ, Chien A, Guimaraes JL, Chappey C, Wang H, Drescher SK, Dall’O’ E, Smith JP, Parmar S, Layman RM, Ma C. Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
6. Nasrazadani A, Tidwell R, Kai M, Lim B, Valero V, Saleem S, Lucci A, Cancer Team MIB, Woodward W, Layman RM. Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
7. Layman R, Liu X, Li B, McRoy L, Chen C, Rocque GB, Brufsky A. Real-world palbociclib dose adjustment and outcomes in HR+/HER2- metastatic breast cancer: Flatiron database analysis. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
8. Nasrazadani A, Layman R, Valero V, Saleem S, Lucci A, Baranov O, Kushnarev V, Butusova A, Menshikova S, Gokin A, Novokreshenova A, Chernyshov K, Kotlov N, Cancer Team MIB, Woodward W, Lim B. Luminal subtype independent immune-enrichment in inflammatory breast cancer based on commercially available tumor portrait. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
9. Hamilton E, Layman R, Danso M, He W, Fong JN, Pehlivan KC, Patel MR. Efficacy, safety and biomarker results of AC699, a chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
10. Krishnamurthy S, Bassett Jr RL, Nasrazadani A, Layman RM, Lim B, Sun SX, Kai M, Ueno N, Tripathy D, Valero V, Lucci A, Woodward W, Cancer Team MIB. Development and validation of Residual tumor Burden calculator specific for Inflammatory breast carcinoma (IBC) to predict outcome (R-IBC). 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
11. Hawkins-Westergard D, Dimitrijevic A, Yam C, Layman RM, Ueno NT, Arun B, Lee J. Overcoming Olaparib Resistance in BRCA-Mutated Triple-Negative Breast Cancer: Synergistic Potential of DNA Repair Pathway Inhibitors. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
12. Chen J, Meas S, Slack Tidwell BS, Sarli VN, Upshaw J, Cancer Team MIB, Krishnamurthy S, Valero V, Layman RM, Nasrazadani A, Sun SX, Lim B, Woodword WA, Lucci A. Preoperative Predictors of Nodal pCR for Potential De-escalation of Axillary Surgery in Inflammatory Breast Cancer. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
13. Akkoc Mustafayev FN, Mustafayev NA, Gutierrez AM, Pasyar S, Yam C, Layman RM, Kizub D, Bassett R, Arun B. Clinical Outcomes and the 21-Gene Recurrence Score Assay in Early-Stage Breast Cancer Associated with CHEK2, ATM and PALB2 Germline Pathogenic Variants. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
14. Wander SA, Kalinsky K, Jeselsohn R, Bianchini G, Hamilton E, Martin M, Hurvitz S, Sammons S, Kaufman PA, Demirci U, Layman RM, Knoderer H, Won H, Zhou Y, Ravenberg E, Sandoval C, Nguyen B, Litchfield LM, Graff SL. Genomic profiling of ctDNA & assoc. w/ efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy. 2024 San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
15. Layman R, Rugo HS, Wesolowski R, Han H, Specht JM, Dees E, Stringer-Reasor EM, Kabos P, Abramson V, Shields A, Moser C, Gorbatchevsky I, Nayak P, Suzuki S, Mutka S. Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
16. Patnaik A, Powell D, Chourasia AH, Cristofanilli M, Morawa E, Barton J, Layman RM, Goetz M. First-in-human Phase 1 study of BTX-9341, a first-in-class, CDK4/6 bifunctional degrader, as a monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer. 2024 San Antonio Breast Cancer Symposium 31(12), 2025. e-Pub 2025.
17. Mouabbi JA, Sakr Y, Raghavendra AS, Abualkhair OA, Barcenas CH, Damodaran S, Layman RM, Tripathy D, Pohlmann PR. Real-world effectiveness of trastuzumab deruxtecan (T-DXd) in endocrine therapy (ET)-refractory metastatic invasive lobular carcinoma (mILC) with HER2-low wild type (HER2wt) versus HER2-low mutant (HER2m). 2025 ESMO Congress 10(4):Presentation #329P, 2025. e-Pub 2025.
18. Brufsky AM, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu PH, Curigliano G, Rugo HS. Real-world effectiveness of palbociclib (PAL) in combination with an aromatase inhibitor (AI) vs AI alone in HR+/HER2- bone-only metastatic breast cancer (MBC). 2025 ESMO Congress 10(4):Presentation #319P, 2025. e-Pub 2025.
19. Nasrazadani A, Kai M, Slack R, Valero V, Lim B, Lucci A, Krishnamurthy S, Layman RM, Woodward W. Early brain relapse in stage III inflammatory breast cancer occurs independent of molecular subtype. 2025 ESMO Congress 10(4):Presentation Number: 202P, 2025. e-Pub 2025.
20. Wander S, Hamilton EP, Bianchini G, Kalinsky K, Sammons S, Graff SL, Park KH, Hurvitz SA, Jimenez MM, Demirci U, Kaufman PA, Layman RM, Nguyen B, Knoderer H, Rubenstein CS, Amdur S, Ravenberg E, Won H, Litchfield LL, Jeselsohn R. Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients. 2025 ESMO Congress 10(4):Presentation #6MO, 2025. e-Pub 2025.
21. Mouabbi J, Sakr Y, Raghavendra AS, Adesoye T, Kuerer H, Nasrazadani A, Hassan A, Bisen A, Moscol G, Valero V, Barcenas C, Tripathy D, Middleton L, Layman R, Pohlmann P, Meric-Bernstam F. Outcomes of neoadjuvant endocrine therapy (NAET) versus neoadjuvant chemotherapy (NAC) in stage II-III invasive lobular carcinoma (ILC). 2025 ASCO Annual Meeting 43(16):Abstract # 603, Poster Bd #196, 2025. e-Pub 2025.
22. Mouabbi J, Kushnarev V, Goncharova D, Baranov O, Chernyshov K, Kotlov N, Paradiso F, Hensley M, Layman R, Tripathy D, Pohlmann P, Meric-Bernstam F. Macroscale genomic alterations in histomolecular invasive lobular carcinoma compared to other breast cancer subtypes. 2025 ASCO Annual Meeting 43(16):Abstract #1049, Poster Bd #28, 2025. e-Pub 2025.
23. LoRusso P, Mukohara T, Sommerhalder D, Yonemori K, Hamilton E, Layman R, Kim S, Im S, Rugo H, Yamashita T, Yan F, Hara F, Kim GM, Wang S, Kent S, Liu L, Skoura A, Kowalski K, Li M, Park YH. Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D). 2025 ASCO Annual Meeting 43(16):Abstract # 1020, 2025. e-Pub 2025.
24. Braschi E, Corrigan K, Yang Y, Stauder M, Woodward W, Layman R, Lim B, Arnold T, Lucci A, Sun S, Saleem S, Ludmir E. Rare but relevant: exploring factors behind inflammatory breast cancer’s exclusion from breast cancer clinical trials. 2024 ASTRO Annual Meeting 120(2):e298-e299, 2024. e-Pub 2024.
25. Mouabbi AA, Raghavendra AS, Pasyar S, Bassett Jr RL, Nasrazadani A, Barcenas CH, Hassan AA, Tripathy D, Layman RM. MDA iLobulaRx: An Advanced Clinico-Patho-Therapeutic Tool for Risk Stratification in Early-Stage Invasive Lobular Carcinoma. 2024 San Antonio Breast Cancer Symposium 31(12), 2024. e-Pub 2024.
26. Kalinsky K, Bianchini G, Hamilton EP, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons SL, Kaufman PA, Muñoz M, Tseng LM, Knoderer H, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Wander SA. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. 2024 Annual ASCO Meeting 42(17):Abstract LBA1001, 2024. e-Pub 2024.
27. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Mishra NH, Maity A, Bogg O, Liu L, Li M, LoRusso P. A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer. 2024 ASCO Annual Meeting 42(16):Abstract 3006, 2024. e-Pub 2024.
28. Patel MR, Layman RM, Danso MA, Cosgrove D, Zettler ME, Pehlivan KC, Hamilton EP. Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer. 2024 ASCO Annual Meeting 42(16):3074, Poster Bd #219, 2024. e-Pub 2024.
29. Mouabbi JA, Meric-Bernstam R, Nasrazadani A, Nelson BE, Salem B, Kushnarev V, Tkachuk A, Sotova M, Polyakova M, Baranov O, Turova P, Chernyshov K, Kotlov N, Brown JH, Clayton P, Sarachakov A, Postovalova E, Bagaev A, Tripathy D, Layman RM. The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast. 2024 ASCO Annual Meeting 42(16):1044, Poster #22, 2024. e-Pub 2024.
30. Mouabbi JA, Meric-Bernstam F, Bassett R, Tripathy D, Layman R. Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) (ID 419). 2024 ESMO Breast Cancer 9:103246, Article 103246, 2024. e-Pub 2024.
31. Nasrazadani A, Slack R, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Lucci A, Woodward W, Layman R. Poor response to cyclin dependent kinase 4/6 inhibition in metastatic inflammatory breast cancer (ID 417). 2024 ESMO Breast Cancer 9(4):103244, Abstract 222P, 2024. e-Pub 2024.
32. Alexander A, Murphy H, Reuben J, Le-Petross HTC, Lane D, Huang M, Krishnamurthy S, Gong Y, Gombos D, Patel N, Allen R, Liu S, Patel A, Futreal A, Wistuba I, Layman R, Ueno N, Tripathy D, Lim B, Valero V. Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory breast cancer (IBC): Clinical data of both cohorts. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO5-06-02, 2024. e-Pub 2024.
33. Iwase T, Nithya S, Kai M, Willey J, Dong W, Shen Y, Krishnamurthy S, Lucci A, Le-Petross HTC, Nasrazadani A, Saleem S, Layman R, Valero V, Tripathy D, Woodward W, Cheng YC, Nakhlis F, Bellon J, Lynce F, Ueno N. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO5-01-03, 2024. e-Pub 2024.
34. Patel MR, Layman R, Fong JN, Zhang H, Kim S, Hamilton E. AC699-001, a first in human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO3-19-07, 2024. e-Pub 2024.
35. Tarantino P, Niman S, Giordano A, Nakhlis F, Bellon J, Woodward W, Nasrazadani A, Saleem S, Lucci A, DeMeo M, Ueno N, Tolaney S, Valero V, Regan M, Layman R, Lynce F. TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO3-20-06, 2024. e-Pub 2024.
36. Mouabbi J, Pasyar S, Bassett R, Raghavendra AS, Hassan A, Layman R, Tripathy D. MDA iLobular Prognostic Tool: A Novel Approach for Risk Stratification in Invasive Lobular Carcinoma. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO4-02-12, 2024. e-Pub 2024.
37. Mustafayev FA, Munsell M, Layman R, Yam C, Barrera AG, Arun B. Clinical Implications of Body Mass Index (BMI) in BRCA-associated Advanced Breast Cancer Patients Treated With PARP (Poly ADP-Ribose Polymerase) Inhibitors. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO4-06-06, 2024. e-Pub 2024.
38. Claudine Isaacs C, Jerzak K, Hilton J, Guimarães JLM, Layman R, Lu D, Mo G, Calella AM, Valota O, Anderson S, Ma C. TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancer. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO2-20-04, 2024. e-Pub 2024.
39. Valenza C, Trapani D, Zagami P, Antonarelli G, Bielo LB, Nicolò E, Ribeiro JM, Guidi L, REDUZZI C, Spotti M, Munzone E, Cortés J, Pistilli B, Tolaney S, Ueno N, Layman R, Cristofanilli M, Carey L, Lynce F, Woodward W, Curigliano G. Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO1-06-04, 2024. e-Pub 2024.
40. Brufsky A, Liu X, Li B, McRoy L, Chen C, Makari D, Layman R, Rugo H. Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in metastatic breast cancer patients with cardiovascular diseases. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO1-17-05, 2024. e-Pub 2024.
41. Lynce F, Niman S, Gonçalves A, Kai M, Ryan S, Troll E, Layman R, Giordano A, Nasrazadani A, Nakhlis F, Bellon J, Warren L, Block C, Schumer S, Lucci A, Krishnamurthy S, Lerebours F, Dalenc F, Levy C, Petit T, Leheurteur M, Bachelot T, Trédan O, Ladoire S, Almeida LL, Zemmour C, Tolaney S, Valero V, BERTUCCI F, Regan M, Woodward W. Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC). 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO2-03-06, 2024. e-Pub 2024.
42. Ma W, Zhao L, Devi G, Krishnamurthy S, Coffer L, Alexander A, Kai M, Wang X, Le-Petross H, Patel M, Debeb B, Bartholomeusz C, Zhang J, Song X, Futreal A, Ueno N, Layman R, Lucci A, Wang J, Woodward W. Building genomic and transcriptomic data among African American and Black patients with triple-negative inflammatory breast cancer. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO2-09-05, 2024. e-Pub 2024.
43. Mustafayev FNA, Munsell M, Gutierrez-Barrera AM, Yam C, Layman RM, and Arun B. Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience. 2023 ASCO Annual Meeting 41(16):Abstract #10587, Poster Bd # 220, 2023. e-Pub 2023.
44. Layman RM, Jerzak KJ, Hilton JF, Clifton K, Alkuzweny B, Mo G, Valota O, Smith JP, Anderson S, Ma CX. TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer. 2023 ASCO Annual Meeting 41(16):TPS1121, 2023. e-Pub 2023.
45. Mouabbi J, Qiao W, Raghavendra AS, Shen Y, Tripathy D, Layman RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. 2023 ESMO Breast Cancer 8(1, Supplement 4):101427, Abstract 239P, 2023. e-Pub 2023.
46. Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Real-World Effectiveness of Palbociclib Plus an Aromatase Inhibitor vs AI Alone in Patients Who Have Metastatic Breast Cancer With Lung or Liver Metastases. 2023 ESMO Breast Cancer 8(1, Supplement 4):101412, Abstract 223P, 2023. e-Pub 2023.
47. Hs R, Robert Wesolowski R, Stringer-Reasor EM, Han H, Specht JM, Dees EC, Kabos P, Vaishampayan U, Wander SA, Lu J, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Gorbatchevsky I, Layman RM. Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor-positive advanced breast cancer: updated results in treatment-naïve patients. 223 ESMO Breast Cancer 8(1, Supplement 4):101393, Abstract 204P, 2023. e-Pub 2023.
48. Cobb AN, Lucci A, Kuerer H, Teshome M, Woodward W, Ueno NT, Stauder M, Layman RM, Sun S. Long-term oncologic outcomes in inflammatory breast cancer patients with supraclavicular nodal involvement 29(10):6381-92, 2022. e-Pub 2022. PMID: 35834145.
49. Kalinsky K, Layman RM, Kaufman PA, Graff SL, Bianchini G, Martin M, Zhou Y, Knoderer H, Litchfield L, Wander SA. postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. 2022 ASCO Annual Meeting. Citation: J Clin Oncol 40(Supp 16), 2022. e-Pub 2022.
50. Layman R, Wesolowski R, Han H, Specht JM, Stringer-Reasor EM, Dees E, Kabos P, Mayer IA, Vaishampayan U, Lu J, Gogineni K, Bardia A, Schott AF, Abu-Khalaf M, Howkins D, Sullivan B, Gorbatchevsky I, Rugo H. Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer 82(4):Abstract PD13-02, 2022. e-Pub 2022.
51. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer with Lung/Liver Metastases: Flatiron Database Analysis. 2021 San Antonio Breast Cancer Symposium 82(4):Abstract P1-18-20, 2022. e-Pub 2022.
52. Kalinsky K, Abramson V, Chalasani P, Linden HM, Alidzanovic J, Layman RM, Vranjes Z, Nangia JR, Crew KD, Andric Z, Milovic-Kovacevic M, Trifunovic J, Suarez J, Suster M, Ptaszynski M, Mortimer J. ZN-c5, an oral selective estrogen receptor degrader, in women with advanced estrogen receptor-positive/HER2- breast cancer. 2021 San Antonio Breast Cancer Symposium 82(4):Abstract P1-17-02, 2022. e-Pub 2022.
53. Layman RM, Wesolowski R, Han H, Specht JM, Stringer-Reasor EM, Dees EC, Kabos P, Mayer IA, Vaishampayan JL, Lu J, Gogineni K, Bardia A, Schott AF, Abu-Khalaf MM, Hawkins D, Sullivan B, Gorbatchevsky I, Rugo HS. Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ advanced breast cancer. 2021 San Antonio Breast Cancer Symposium 82(4):Abstract PD13-02, 2022. e-Pub 2022.
54. Patt DA, Liu X, Li B, McRoy L, Layman RM, Brufsky A. Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer. 2021 ASCO Annual Meeting. Citation: J Clin Oncol 39(Suppl 15), 2021. e-Pub 2021.
55. Hobbs E, Lindquist E, Sullivan B, Yoon E, Yuan Y, Marx A, Willey J, Sun H, Layman RM, Stover D, Yuan Y, Lim B. Neratinib and tepotinib combination in advanced breast cancer and inflammatory breast cancer patients with abnormal HER2 and c-Met pathway activity as measured by the CELsignia signaling pathway activity test. 2020 San Antonio Breast Cancer Virtual Symposium 81(4):Abstract OT-28-04, 2021. e-Pub 2021.
56. Shukla MA, Gutierrez Barrera A, Gruschkus SK, Layman RM, Murthy RK, Arun BK. Characteristics of HER2/neu positive breast cancer among patients with and without germline BRCA mutations. 2020 San Antonio Breast Cancer Virtual Symposium 81(4):Abstract PS4-31, 2021. e-Pub 2021.
57. Arun B, Zhao L, Bassett RL, Thompson AM, White JB, Layman RM, Gutierrez Barrera A, Valero V, Ueno NT, Litton JK, Zhang J, Ravenberg E, Candelaria RP, Rauch GM, Tripathy D, Moulder SL. Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial. 2020 ASCO Annual Meeting (Virtual) 38(15):Abstract #1546, Poster Bd #38, 2020. e-Pub 2020.
58. Rugo HS, Bardia A, Han H, Layman RM, Kern K, Dees E, Forero A, Pathan N, pierce KJ, Lu MJ, Wesolowski R, Kabos P, Houk B. Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy in women with estrogen receptor positive metastatic breast cancer, 2020. e-Pub 2020.
59. Arun B, Gutierrez Barrera A, Layman RM, Gruschkus SK, Bedrosian I, Albarracin CT, Barcenas CH, Valero V, Litton JK, and Tripathy D. Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort. Poster session. 2020 ASCO Annual Meeting (Virtual) 38(15, Supplement 1544):Abstract #1544, Poster Bd # 36, 2020. e-Pub 2020.
60. Lim B, Seth S, Huo L, Layman RM, Valero V, Thompson AM, White JB, Litton JK, Damodaran S, Candelaria RP, Arun B, Rauch GM, Murthy RK, Ding Q, Symmans WF, Zhao L, Zhang J, Tripathy D, Moulder SL, Ueno NT. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. Poster discussion session. 2020 ASCO Annual Meeting (Virtual) 38(15):Abstract 517, Poster Bd # 9, 2020. e-Pub 2020.
61. Wesolowski R, Pathan N, Zhu Z, Stringer-Reasor EM, Han HS, Dees EC, Bardia A, Layman RM, Weise A, Kabos P, Lu JM, Kern KA, Pierce KJ, Hope AR. Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC). 2020 ASCO Annual Meeting (Virtual) 38(15, Supplement 1052):1052, Poster Bd # 137, 2020. e-Pub 2020.
62. Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, De Vita S, Kundamal N, He W, Balbin A, Sheng Q, Crystal A, and Curigliano G. LBA1-Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET). 2020 ESMO Breast (Virtual) 31(2):S62, 2020. e-Pub 2020.
63. Quiroga DM, Stiff A, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman R, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace T, Yu L, Duggan M, Carson WE, and Wesolowski R. Analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients pre- and post-neoadjuvant chemotherapy for operable breast cancer. Session PO.IM02.16 - Immune Response to Therapies 1 Session PO.IM02.16 - Immune Response to Therapies 1, 2020. e-Pub 2020.
64. Jhaveri K, Juric D, Cresta S, Yap YS, Duhoux FP, Terret C, Layman R, Balbin A, Sheng Q, Liao S, Crystal A, Curigliano G. Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC. 2019 San Antonio Breast Cancer Symposium 80(4):Abstract P4-10-07, 2020. e-Pub 2020.
65. Du L, Yau C, Brown-Swigart L, Gould R, Gillian L Hirst GL, Consortium I, van der Noordaa M, Bedrosian I, Layman RM, Valero V, van't Veer L, Esserman L, and Symmans WF. Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. 2019 San Antonio Breast Cancer Symposium 80(4):Abstract P2-11-04, 2020. e-Pub 2020.
66. Jhaveri K, Juric D, Cresta S, Yap YS, Duhoux FP, Terret C, Layman R, Kundamal N, Liao S, Ji Y, Crystal A, Curigliano G. A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET). 2019 San Antonio Breast Cancer Symposium 80(4):Abstract PD7-09, 2020. e-Pub 2020.
67. DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Rugo HS, and Finn RS. Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. 2019 San Antonio Breast Cancer Symposium 80(4):Abstract P1-19-02, 2020. e-Pub 2020.
68. Iwases T, Harano K, Masuda H, Kida K, Fermandez JRE, Hess KR, Wang Y, Baggerly KA, Dirix L, Woodward WA, Layman RM, Van Laere SJ, Bertucci F, Bertucci F, Ueno NT. Myc as a poor prognostic marker for ER+ inflammatory breast cancer (IBC): Quantitative ER expression analysis and gene expression analysis in ER+ IBC vs non-IBC. 2018 San Antonio Breast Cancer Symposium 79(4):Abstract P5-05-04, 2019. e-Pub 2019.
69. Yam C, Raghanvendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendor EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. 2018 San Antonio Breast Cancer Symposium 79(4):Abstract P1-15-06, 2019. e-Pub 2019.
70. Curigliano G, Cresta S, Yap YS, Juric D, Duhoux FP, Terret C, Takahashi S, Layman RM, Kundamal N, Baldon D, Liao S, Crystal AS, Jhaveri K. Phase I/Ib study of oral selective estrogen receptor degrader (SERD) in combination with Alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with progression on endocrine therapy (ET). 2018 San Antonio Breast Cancer Symposium 79(4):Abstract OT1-03-01, 2019. e-Pub 2019.
71. Forero-Torres A, Han H, Dees EC, Wesolowski R, Bardia A, Kabos P, Layman RM, Lu JM, Kern KA, Perea R, Pierce KJ, Houk B, Pathan N, S Rugo AH. Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009). 2018 ASCO Annual Meeting 36(15):Abstr 1040, Poster Bd #121, 2018. e-Pub 2018.
72. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss A, Huebner L, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Toppmeyer D, Velasco M, Perez EA, Hudis CA, Winer E. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone+/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. 2017 San Antonio Breast Cancer Symposium 78(4):Abstract GS3-06, 2018. e-Pub 2018.
73. Layman RM, Ma CX, Bardia A, Karuturi MS. Treatment beyond progression on cyclin-dependent kinase 4/6 inhibitors: Clinical trials in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. 2017 Miami Breast Cancer Conference, 2017.
74. Lustberg MB, Monfort S, Singaravelu J, Reinbolt RE, Pan X, Ramaswamy B, Layman RM, Wesolowski R, Mrozek E, Macrae E, Shapiro C, Patrick R, Loprinzi CL, Chaudhari A. Longitudinal evaluation of taxane-induced neuropathy in early stage breast cancer. 2014 San Antonio Breast Cancer Symposium 75(9):Abstract P1-09-04, 2016. e-Pub 2016.
75. Reinbolt RE, Tolliver K, Abdel-Rasoul M, Timmers C, Ramaswamy B, Layman RM, Wesolowski R, Lustberg MB, Mrozek E, Ottman S, Chen J, Shapiro C, Ostrowski MC, Leone GW, Macrae E. Incidence of actionable genomic alterations in metastatic breast cancer: A prospective study. 2014 San Antonio Breast Cancer Symposium 75(9):Abstract P2-03-03, 2015. e-Pub 2015.
76. Lustberg MB, Orchard T, Pan X, Reinbolt R, Logan A, Lester J, Layman RM, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Berger M, Knopp M, Loprinzi C, Shapiro CL, Yee L. Prevention of aromatase Inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot study. 2014 San Antonio Breast Cancer Symposium 75(9):Abstract P1-09-03, 2015. e-Pub 2015.
77. Reinbolt RE, Pan X, Wandell K, Pilarski R, Layman RM, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg MB. Impact of breast cancer treatment on body mass index (BMI) over time, 2015. e-Pub 2015.
78. Wesolowski R, Zhao M, Geyer SM, Lustberg MB, Mrozek E, Layman RM, Macrae EM, Zhang J, Hall N, Schregel K, Ottman S, Camp A, Chalmers JJ, Andreopoulou E, Villalona-Calero MA, Shapiro CL, Knopp MV, Grever MR, Ramaswamy B. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC). 2014 ASCO Annual Meeting 32(15):Abstract 1074, Poster Bd #167, 2014. e-Pub 2014.
79. Mrozek E, Wesolowski R, Lustberg MB, Layman RM, Ling Y, Schaaf LJ, Phelps MA, Ivy SP, Grever MR, Shapiro CL. A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC). 2013 ASCO Annual Meeting 31(15):Abstract 1043, Poster Bd #19B, 2013. e-Pub 2013.
80. Ramaswamy B, Zhang J, Hall N, Schregel K, Lustberg MB, Wesolowski R, Mrozek E, Layman RM, Olson EM, Ottman S, Camp A, Chalmers JJ, Geyer SM, Villalona-Calero MA, Shapiro CL, Grever MR, Knopp MV. NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer. 2013 ASCO Annual Meeting 31(15):Abstract 1023, Poster Bd #15, 2013. e-Pub 2013.
81. Lustberg MB, Ruppert AS, CarothersS, Bingman A, McCarthy B, Raman S, Das M, Kanji S, Lu J, Das H, Cinar-Akakin H, Gurcan MN, Berger MJ, Wesolowski R, Olson EM, Ramaswamy B, Mrozek E, Layman RM, Binkley P, Shapiro CL. Endothelial progenitor cells as novel markers of anthracycline induced cardiac injury. 2012 San Antonio Breast Cancer Symposium 72(24):Abstract P2-11-07, 2012. e-Pub 2012.
82. Ramaswamy B, Lustberg MB, Wesolowski R, Layman RM, Mrozek E, Olson EM, Andreopoulou E, Garcia-Villa A, Chalmers J, Cotrill JA, Nutter J, Ledin J, Schaaf LJ, Bajestani S, Zhao W, Geyer S, Chen A, Shapiro CL, Villalona-Calero MA, Knopp M, Grever MR. Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609). 2012 ASCO Annual Meeting 72(8):Abstract 5586, 2012. e-Pub 2012.
83. Ramaswamy B, Srividya V, Mullins DA, Carothers S, Young G, Wenrui D, Zhao W, Lustberg M, Leon M, Weslowski R, Layman R, Mrozek E, Shapiro CL, Villalona-CaleroM. Prevalence of dysfunctional fanconi anemia (FA) DNA repair pathway in breast cancer. 2011 San Antonio Breast Cancer Symposium 71(24):Abstract PD10-01, 2011. e-Pub 2011.
84. Hurvitz S, André F, Cristofanilli M, Curigliano G, Giordano A, Han H, Martín M, Pistilli B, Rugo H, Wesolowski R, Gorbatchevsky I, Loibl S. A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1). 2023 San Antonio Breast Cancer Symposium.
85. Mughees M, Tacam M, Tan A, White M, Debeb B, Villodre E, Hu X, Tripathy D, Woodward W, Layman R, Bartholomeusz G, Bartholomeusz C. A selective MCL-1 inhibitor AZD5991 showed tumor regression in a triple-negative inflammatory breast cancer xenograft model. 2023 San Antonio Breast Cancer Symposium 84(9):Abstract PO2-14-10.
86. Nasrazadani A, Tidwel B, Kai M, Mouabbi J, Lim B, Valero V, Saleem S, Woodward WA, Layman RM. Invasive lobular carcinoma is rarely seen in inflammatory breast cancer and confers an inferior prognosis. 2024 International Invasive Lobular Breast Cancer Symposium.

Book Chapters

1. Layman RM. Special Situations in Breast Cancer. In: The MD Anderson Manual of Medical Oncology. 4. ‎ McGraw Hill, 2022.
2. Layman RM, Sukumar JS. Special Situations in Breast Cancer. In: 5th edition - MD Anderson Manual of Medical Oncology.
3. Saxena K, Layman RM. Systemic Therapy, Hormone Receptor Positive Breast Cancer. In: Cancer Medicine Holland/Frei Textbook. 10.